Literature DB >> 17454637

Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin.

Duncan H Mak1, Wendy D Schober, Wenjing Chen, Jonathan Heller, Michael Andreeff, Bing Z Carter.   

Abstract

Tetra-O-methyl nordihydroguaiaretic acid (M4N) was shown to induce G2 arrest and suppress human xenograft tumor growth by inhibiting Cdc2 and survivin. We examined the effect of M4N on leukemia and found that M4N inhibited growth and induced cell death in leukemic cell lines and blasts from AML patients. However, no significant changes in Cdc2 and survivin levels and G2 arrest were observed. Cell death and growth inhibition were dependent neither on XIAP, Bcl-2, and Bcl-X(L) levels nor on caspase-8. M4N did not promote cell differentiation in HL-60 cells. Interestingly, significant inhibition of AKT phosphorylation was observed in M4N treated OCI-AML3 cells. Collectively, our data showed that M4N inhibited cell growth and induced cell death in both leukemic cell lines and AML patient sample via a mechanism not mediated by Cdc2 and survivin inhibition and suggested that the extrinsic and the mitochondrial apoptotic pathways are not essential.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17454637     DOI: 10.1080/10428190601186143

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

Review 1.  Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: an update.

Authors:  Jian-Ming Lü; Jacobo Nurko; Sarah M Weakley; Jun Jiang; Panagiotis Kougias; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Med Sci Monit       Date:  2010-05

2.  Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.

Authors:  Angel Mauricio Castro-Gamero; Kleiton Silva Borges; Daniel Antunes Moreno; Veridiana Kill Suazo; Mayara Missono Fujinami; Rosane de Paula Gomes Queiroz; Harley Francisco de Oliveira; Carlos Gilberto Carlotti; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Invest New Drugs       Date:  2013-01-09       Impact factor: 3.850

3.  Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias.

Authors:  R Tibes; K T McDonagh; L Lekakis; J M Bogenberger; S Kim; N Frazer; S Mohrland; D Bassett; R Garcia; K Schroeder; V Shanmugam; J Carpten; R T Hagelstrom; C Beaudry; D Von Hoff; T C Shea
Journal:  Invest New Drugs       Date:  2014-12-19       Impact factor: 3.850

4.  Terameprocol (tetra-O-methyl nordihydroguaiaretic acid), an inhibitor of Sp1-mediated survivin transcription, induces radiosensitization in non-small cell lung carcinoma.

Authors:  Yunguang Sun; Nicholas J Giacalone; Bo Lu
Journal:  J Thorac Oncol       Date:  2011-01       Impact factor: 15.609

5.  Phase I study of terameprocol in patients with recurrent high-grade glioma.

Authors:  Stuart A Grossman; Xiaobu Ye; David Peereboom; Myrna R Rosenfeld; Tom Mikkelsen; Jeffrey G Supko; Serena Desideri
Journal:  Neuro Oncol       Date:  2012-02-08       Impact factor: 12.300

6.  Quantitation of terameprocol in human plasma by liquid chromatography-tandem mass spectrometry.

Authors:  Nicole M Anders; Carlos G Romo; Avelina Hemingway; Manmeet S Ahluwalia; Michelle A Rudek
Journal:  J Pharm Biomed Anal       Date:  2021-12-07       Impact factor: 3.935

7.  Repurposing Drugs by In Silico Methods to Target BCR Kinase Domain in Chronic Myeloid Leukemia.

Authors:  Aparna Natarajan; Rajkumar Thangarajan; Sabitha Kesavan
Journal:  Asian Pac J Cancer Prev       Date:  2019-11-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.